Randomized, double-blind, placebo-controlled phase 2a study assessing the efficacy and safety of felzartamab for IgA nephropathy

202514 citationsJournal Articlehybrid Open Access

Authors

Registered at ClinicalTrials.gov with study number NCT05065970.

Published in: Kidney International

Volume 108, Issue 4, pp. 695-706

Field-Weighted Citation Impact: 20.14